Literature DB >> 3242681

Location of disulphide bonds in human insulin-like growth factors (IGFs) synthesized by recombinant DNA technology.

F Raschdorf1, R Dahinden, W Maerki, W J Richter, J P Merryweather.   

Abstract

Natural human insulin-like growth factor (IGF) I is a relatively large single chain peptide (mol. wt 7649) with a known sequence of 70 amino acids. C6----C48, C47----C52 and C18----C61 assignments have been previously proposed for the three disulphide bonds linking six cysteine residues (C6, C18, C47, C48, C52 and C61), on the basis of analogy (and homology) with proinsulin. In this work, IGF I synthesized by recombinant DNA technology (r-IGF I, with identical biological activity and chromatographic behaviour) was subjected to a three-step mass spectrometric analysis in combination with degradation methods for structural verification. Firstly, the correct molecular weight of the intact peptide was determined by high-mass fast atom bombardment (FAB) analysis. Secondly, twofold enzymatic degradation (chymotrypsin followed by V8 protease, 'FAB mapping' of the cleavage products) was employed in order that fragments with 'isolated' S-S bonds would be produced which allow an unambiguous assignment. This immediately established the C18----C61 linkage as it was contained in a singly bridged two-chain peptide. The two other S-S bonds, which cross-link C6 and the 'tight' C47 to C52 segment, remained 'unresolved' within a more complex, doubly bridged triple-chain peptide. Thirdly, further degradation of this structural block, in which cleavage of the C47-C48 bond was required to discern these bonds, was carried out by using FAB tandem mass spectrometry and (for additional corroboration) manual Edman degradation. Both procedures confirmed the original C6----C48/C47----C52 prediction.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3242681     DOI: 10.1002/bms.1200160102

Source DB:  PubMed          Journal:  Biomed Environ Mass Spectrom        ISSN: 0887-6134


  7 in total

1.  Analysis of the extent of unfolding of denatured insulin-like growth factor.

Authors:  J Y Chang; W Märki; P H Lai
Journal:  Protein Sci       Date:  1999-07       Impact factor: 6.725

2.  Chemical heterogeneity as a result of hydroxylamine cleavage of a fusion protein of human insulin-like growth factor I.

Authors:  E Canova-Davis; M Eng; V Mukku; D H Reifsnyder; C V Olson; V T Ling
Journal:  Biochem J       Date:  1992-07-01       Impact factor: 3.857

3.  Separation and characterization of modified variants of recombinant human insulin-like growth factor I derived from a fusion protein secreted from Escherichia coli.

Authors:  G Forsberg; G Palm; A Ekebacke; S Josephson; M Hartmanis
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

4.  Yeast-derived recombinant human insulin-like growth factor I: production, purification, and structural characterization.

Authors:  S Elliott; K D Fagin; L O Narhi; J A Miller; M Jones; R Koski; M Peters; P Hsieh; R Sachdev; R D Rosenfeld
Journal:  J Protein Chem       Date:  1990-02

Review 5.  Mass spectrometry-based methods in characterization of the higher order structure of protein therapeutics.

Authors:  Igor A Kaltashov; Cedric E Bobst; Jake Pawlowski; Guanbo Wang
Journal:  J Pharm Biomed Anal       Date:  2020-02-12       Impact factor: 3.935

6.  Disulfide structures of highly bridged peptides: a new strategy for analysis.

Authors:  W R Gray
Journal:  Protein Sci       Date:  1993-10       Impact factor: 6.725

Review 7.  Procollagen type III amino-terminal propeptide and insulin-like growth factor I as biomarkers of growth hormone administration.

Authors:  David A Cowan; Danielle A Moncrieffe
Journal:  Drug Test Anal       Date:  2021-09-06       Impact factor: 3.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.